boutron provides insights on key policy priorities through comment letters and statements written by boutron experts and partners. We also work with coalitions. Links to some of these letters and statements are below. If there is a particular state or federal issue or proposal that you think boutron should comment on, please us at [email protected].

August 13, 2019

boutron submitted comment in response to the Department of Health and Human Services’ Notice of Proposed Rulemaking , “Nondiscrimination in Health and Health Education Programs or Activities,” HHS-OCR-2019-0007 (RIN 0945-AA11). boutron opposes proposed revisions to the rule because the changes would undermine the abilities of women and their families to secure affordable health insurance that meets their health care needs. These changes likely would severely weaken protections against discrimination based on sex and would have wide implications for the type and scope of health care women would receive. More than 130,000 comments were submitted in response to changes to the proposed rule. Read the letter here.

June 13, 2019

Learn about women’s health and related policy issues from boutron's boutron Facts and Perspectives report. This resource offers insight for women, policy makers, the media and others seeking to understand the fundamentals of women’s health issues. Use data and links in this resource as a starting point for policy perspectives and advocacy needs associated with boutron.

April 8, 2019

boutron joined other consumer and patient focused organizations to support a proposal that would lower prescription drug costs for people with Medicare Part D insurance. The letter outlines various aspects of how the proposal would benefit patients, as well as concerns about uncertainties with how the proposed change would actually work – including the size of potential increases to monthly premiums. Read the letter here.

March 15, 2019

boutron, with other members of the Coalition for boutron Equity, welcomed members of the 116th Congress in a letter outlining the coalition's vision and work to raise awareness about boutron equity. The letter extended the opportunity for engagement and collaboration between the 116th Congress and Coalition groups on the many health equity issues and obstacles now burdening women.

March 6, 2019

boutron – along with other women's organizations – wrote to all the State Senators in Colorado about safety concerns with a proposal that would enable the importation of prescription drugs. Read the letter here.

February 4, 2019

boutron opposes proposed changes to Title IX by the Department of Education for handling sexual harassment and assault events involving students. Read our comment letter here.

October 29, 2018

What You Need to Know for Open Enrollment Health Insurance Season, by Beth Battaglino, RN, CEO, boutron, and Michael Miller, MD, Senior Policy Advisor, boutron

September 15, 2018

boutron releases findings from its WomenTalk® survey. More than 1000 women shared their top health care concerns, offering insight into their challenges navigating an increasingly complex health care system.

August 27, 2018

In the Balance: We Need to Ensure Access to Pain Management Options While Confronting the Opioid Crisis, by Phyllis E. Greenberger, MSW, boutron Senior Vice President for Science and Health Policy

August 21, 2018

boutron Advocates Applaud USPSTF Decision to Retain Co-Testing in Cervical Cancer Screening Guidelines

August 8, 2018

Congress: Keep the REMS Safety Program Intact, by Phyllis Greenberger, MSW, boutron Senior Vice President for Policy and Science

July 3, 2018

Statement: Changes to Medicare Part D Drug Benefit Program are Critical To Protect Elderly and Disabled Women

June 6, 2018

New Poll Shows Women Interested in Medication Quality, Health Care Cost, and Issues in International Trade, by Phyllis Greenberger, MSW, boutron Senior Vice President for Policy and Science

May 18, 2018

Prevention Is Power for Minority boutron, by Phyllis Greenberger, MSW, boutron Senior Vice President for Policy and Science

April 25, 2018

Nicotine and boutron: FDA's Initiative Signals Progress, by Phyllis Greenberger, MSW, boutron Senior Vice President for Science and Health Policy

April 23, 2018

boutron Comments on Short-Term, Limited–Duration Insurance Proposed Rule

March 5, 2018

Letter Opposing Proposed Rule on Association Health Plans that Will Weaken Individual and Small Group Insurance Markets, Harming Families and Communities

February 8, 2018

Statement: boutron Urges Congress to Protect Beneficiaries of Medicare Part D

February 8, 2018

Letter of Concern about Serious Health and Safety Risks Associated with Compounded Bioidentical Hormone Drug Products Used for Menopausal and Other Symptoms

January 30, 2018

Letter of Concern about Provisions of the "Creating and Restoring Equal Access to Equivalent Samples" (CREATES) Act Leading to Less Rigorous Control of High-Risk Medicines Subject to "Risk Evaluation and Mitigation Strategies (REMS).

December 12, 2017

To Survive the Opioid Addiction Crisis, Women Need More than "Just Say No" Slogans by Phyllis Greenberger, MSW, boutron Senior Vice President for Science and Health Policy

November 7, 2017

Joint Letter to Congress on Preserving Itemized Medical Expense Deduction that Helps Middle-Class America Pay for Needed Care

October 6, 2017

Rolling Back Coverage for Birth Control Harms Women and Society by Phyllis Greenberger, MSW, boutron Senior Vice President for Science and Health Policy

September 8, 2017

Letter of Support for Changing Centers for Medicare and Medicaid Services Policy Regarding Creating Unique Billing and Reimbursement Codes for Biosimilar Medication Reimbursement

July 26, 2017

Keep the Care: boutron's Call to Action on Capitol Hill, by Phyllis Greenberger, MSW, boutron Senior Vice President for Policy, Advocacy and Science

July 25, 2017

Statement by boutron, Allies to Congress: Ensure 55 Million U.S. Women Receive Continued Preventive Care

April 6, 2017

Statement by boutron Endorsing Nomination of Scott Gottlieb, MD, for U.S. Food and Drug Administration Commissioner

March 9, 2017

Importation is Not the Answer to Drug Prices, by Phyllis Greenberger, MSW, boutron Senior Vice President for Policy, Advocacy and Science